Susceptibility-weighted MR imaging (SWI) of basal ganglia iron deposition in the early and advanced stages of Parkinson's disease

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease and the first one among the nosological entities of parkinsonism. Susceptibility-weighted imaging (SWI), magnetic resonance imaging (MRI) pulse sequence, which allows the in vivo estimation of the values of iron deposition in different areas of the brain, is a potential technique for the early diagnosis of PD and for the study of the pathogenesis of its complications.

Objective: to compare the values of iron deposition in the basal ganglia in Stages II and III PD and to determine the relationship of clinical findings to the level of iron deposition according to the SWI findings.

Patients and methods. Twenty-four patients with Hoehn and Yahr Stages II (n=24) and III (n=12) PD were examined. All the patients underwent brain MRI on a Siemens TrioTim (3T) MRI scanner by using pulse sequences T1, T2, SWI and subsequently quantifying the iron deposition (SPIN software). The accumulation of iron is visualized as an area of reduced signal intensity on SWI, and its estimation in accordance with the SPIN program has accordingly a smaller value. The regions of interest on both sides were the dentate nucleus, substantia nigra, red nucleus, putamen, globus pallidus, and head of the caudate nucleus. The examination protocol also included tests using the following scales: the Unified Parkinson's Disease Rating Scale (UPDRS), the Mini-Mental State Examination (MMSE), Frontal Assessment Batter (FAB), Freezing of Gait (FOG), Gait and Balance Scale (GABS), the Epworth Daytime Sleepiness Scale, the Parkinson's Disease Quality of Life Questionnaire (PDQ), the Beck Depression Inventory, and the Clock-Drawing Test.

Results and discussion. The investigators found significant (p<0.05) correlations between the clinical picture and the level of iron deposition in the regions of interest in patients with Stage II PD: FOG – left caudate nucleus (r=-0.94); GABS – left caudate nucleus (r=-0.94); and in patients with stage III of the disease: UPDRS (full) – left red nucleus (r=-0.82), right globus pallidus (r=-0,80), left putamen (r=-0,96); UPDRS (Section 2) – left red nucleus (r=-0.77), left globus pallidus (r=-0.84); UPDRS (Section 3) – right putamen (r=-0,85), right globus pallidus (r=-0.78), left globus pallidus (r=-0,92); FOG – left globus pallidus (r=-0.81); GABS – left red nucleus (r=-0.96), left putamen (r=0.82), right putamen (r=-0.89), left globus pallidus (r=-0.82), right globus pallidus (r=-0.85), left caudate nucleus (r=-0.82), right caudate nucleus (r=-0.89); Beck Depression Inventory – right substantia nigra (r=-0.82).

Conclusion. SWI measurement of the values of iron deposition in the structures of the extrapyramidal system in PD provides an additional insight into the pathological processes occurring in them.

1. Levin OS, Fedorova NV. Bolezn' Parkinsona [Parkinson's disease]. Moscow: MEDpress-inform; 2015. 384 p.

2. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin. 1996 May; 14(2):317-35.

3. Kanasi E, Ayilavarapu S, Jones J. The aging population: demographics and the biology of aging. Periodontol 2000. 2016 Oct;72(1):13-8. doi: 10.1111/prd.12126.

4. Litvinenko IV, Odinak MM, Trufanov AG. Bolezn' Parkinsona i sindromy parkinsonizma (Uchebnoe posobie) [Parkinson's disease and parkinsonism syndromes (Textbook)]. SaintPetersburg: ELBI-SPb; 2012. 75 p.

5. Tappakhov AA, Popova TE, Nikolaeva TYa, et al. The genetic basis of Parkinson's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2017;9(1): 96-100. (In Russ.). doi: 10.14412/2074-27112017-1-96-100

6. Rybkina VL, Azizova TV. Risk factors for Parkinson's disease. Nevrologicheskii zhurnal. 2017;22(6):287-94. (In Russ.).

7. Milyukhina IV, Ermolenko EI, Ivanova AS, Suvorov AN. The role of gastrointestinal microbiota in the pathogenesis of Parkinson's disease. Nevrologicheskii zhurnal. 2017;22(6):280-6. (In Russ.).

8. Lhermitte J, Kraus WM, McAlpine D. On the occurrence of abnormal deposits of iron in the brain in Parkinsonism with special reference to its localization. J Neurol Psychopathol. 1924 Nov;5(19):195–208.

9. Rutledge JN, Hilal SK, Silver AJ, et al. Study of movement disorders and brain iron by MR. AJR Am J Roentgenol. 1987 Aug;149(2): 365-79.

10. Wang Z, Luo XG, Gao C. Utility of susceptibilityweighted imaging in Parkinson's disease and atypical Parkinsonian disorders. Transl Neurodegener. 2016 Oct 7;5:17. eCollection 2016.

11. Haacke EM, Xu Y, Cheng YC, et al. Susceptibility weighted imaging (SWI). Magn Reson Med. 2004 Sep;52(3):612-8.

12. Pronin IN, Turkin AM, Dolgushin MB, et al. Tissue contrast due to magnetic susceptibility: application in neuroradiology. Meditsinskaya vizualizatsiya. 2011;(3):75-84. (In Russ.).

13. Zhang W, Sun SG, Jiang YH, et al. Determination of brain iron content in patients with Parkinson’s disease using magnetic susceptibility imaging. Neurosci Bull. 2009 Dec;25(6): 353-60.

14. Wu SF, Zhu ZF, Kong Y, et al. Assessment of cerebral iron content in patients with Parkinson's disease by the susceptibility-weighted MRI. Eur Rev Med Pharmacol Sci. 2014; 18(18):2605-8.

15. Zhang J, Zhang Y, Wang J, et al. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study. Brain Res. 2010 May 12; 1330:124-30.

16. Li DTH, Hui ES, Chan Q, et al. Quantitative susceptibility mapping as an indicator of subcortical and limbic iron abnormality in Parkinson's disease with dementia. Neuroimage Clin. 2018 Jul 27;20:365-373. doi: 10.1016/j.nicl.2018.07.028. eCollection 2018.

17. Dashtipour K, Liu M, Kani C, et al. Iron Accumulation Is Not Homogenous among Patients with Parkinson's Disease. Parkinsons Dis. 2015;2015:324843. doi: 10.1155/2015/324843. Epub 2015 Apr 5.

18. Martin-Bastida A, Lao-Kaim NP, Loane C, et al. Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility. Eur J Neurol. 2017 Feb;24(2):357-365. doi: 10.1111/ene.13208. Epub 2016 Dec 16.

19. Wang JY, Zhuang QQ, Zhu LB, et al. Metaanalysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements. Sci Rep. 2016 Nov 9; 6:36669. doi: 10.1038/srep36669.

20. Trufanov AG. Atrophic changes in the cerebral cortex in Parkinson's disease, complicated by higher-level walking disorders, the possibility of their prediction using MR-morphometry. Luchevaya diagnostika i terapiya. 2013; 4(4):35-41. (In Russ.).

21. Litvinenko IV, Odinak MM, Mogil'naya VI. Pain and depression in Parkinson's disease: new therapeutic possibilities of pramipexol. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;108(11):36-8. (In Russ.).